Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compugen

Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage development and commercialization of Anti-IL 18 binding protein antibodies with potential to treat various types of tumors.

Compugen stock rockets on anti-tumor drug deal with Gilead

FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.

Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

Gilead Sciences, Inc. had strong quarterly results, with total product sales of $6.3 billion and strong growth in HIV and Oncology. The company has several milestones, including the success of Trodelvy with over $1 billion in annualized sales. Gilead Sciences is accelerating its cancer business, with over $3 billion in annualized sales and a goal to contribute 1/3 of revenue by 2030.

Gilead Sciences Is Building A Diversified Portfolio

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced data from follow-up analyses of three studies of Yescarta® (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory (R/R) non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. This included ZUMA-1 (Abstract #4864) showing that patients with refra.

Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the results of four new analyses supporting the use of Tecartus® (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). These results include four-year overall survival (OS) data from the pivotal ZUMA-2 study and primary results from ZUMA-18, an expanded access study, evaluating the CAR T.

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite's Tecartus® in Patients With Aggressive Blood Cancers

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma (LBCL). The analysis, which demonstrated durability of clinical benefit – both high complete response (CR) and objective response rates (ORR), including in patients with MYC and BC.

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). These rankings are based on an in-depth analysis of Gilead's sustainability performance and highlight the.

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Amgen

AstraZeneca

Bristol-Myers

Merck

Novo Nordisk

Novartis

Pfizer

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Chimeric antigen receptor T-cell medicines could have more risks than previously known. Novartis' drug Kymriah is going to be under the most scrutiny for now.

This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks

Chevron

Jefferies Financial Group Inc

Republic Services

Southern Company

Simon Property Group

This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.

Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024

Alnylam Pharmaceuticals

iShares Nasdaq Biotechnology ETF

Regeneron Pharmaceuticals

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally and turnaround off its 52-week lows.

3 biotech powerhouses poised to thrive amid sector rebound

Korn/Ferry Int.

ManpowerGroup

QUALCOMM

Ralph Lauren

Korn Ferry, Gilead Sciences, Qualcomm, Ralph Lauren, and Manpower are identified as five companies with high dividend yields and strong capacity for future dividend increases. Korn Ferry is a leader in leadership and talent consulting services with significant growth opportunities. Gilead Sciences has pivoted towards new products and acquisitions to improve its outlook, though it still faces headwinds from COVID-related revenue decline.

5 Dividend Growth Stocks To Consider Buying

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?

Gilead Sciences Inc. (GILD, Financial) is an American pharmaceutical company specializing in developing and commercializing medicines to treat patients with HIV, large B-cell lymphoma, chronic hepatitis C virus, chronic hepatitis B virus and Covid-19.

Gilead Sciences: The Bull Case Is More Powerful Than You Think

Caribou Biosciences

CRISPR Therapeutics

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

Agilent Technologies

Autodesk

Bank of America

Biogen

Bank of New York Mellon

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Disney

Equifax

Estee Lauder

Emerson Electric

Etsy

Alphabet

Huntington Ingalls Industries

Harley-Davidson

Honeywell

Intercontinental Exchange

International Flavors & Fragrances

Keysight

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The December 2023 Heat Map

Apartment Income REIT Corp

Alexandria Real Estate Equities

COPT Defense Properties

Gaming and Leisure Properties

Healthcare Realty Trust Inc

Host Hotels & Resorts

Johnson Controls

LTC Properties

Banco Santander

Sabra Health Care

Telia Co AB

V.F.

Vici Properties

Telefonica Brasil

September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery lists focus on financial services, healthcare, and real estate sectors by Barron's along with selected “change the world” stocks from Fortune and ten to watch from Bloomberg.

17 Ideal Pre-Crash Recovery December Divi-Dogs

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Data featured in eight presentations include an analysis of clinical outcomes by age from the Phase 3 TROPiCS-02 study of Trodelvy in HR+/HER2.

Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Joseph Catanzaro Perfect. Great. Well, appreciate everybody joining us here on the second day of Piper Sandler's Annual Healthcare Conference.

Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript)

News for Gilead Sciences Stock (GILD)